Billing may be tricky for patients in skilled nursing facility

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 11
Volume 17
Issue 11

Here are some simple things that can be done to keep the billing related to skilled nursing facilities in order. Here’s a scenario that most likely plays out in oncology practices on a routine basis: A Medicare beneficiary arrives at a community offi ce for treatment. She has a blood draw followed by a 2-hour chemotherapy infusion. Th e oncology practice’s offi ce submits a reimbursement claim through Medicare Part B. Two weeks later a notice from Medicare arrives-claim denied!

ABSTRACT: Here are some simple things that can be done to keep the billingrelated to skilled nursing facilities in order.

Here are some simple things that can be done to keep the billing related to skilled nursing facilities in order. Here’s a scenario that most likely plays out in oncology practices on a routine basis: A Medicare beneficiary arrives at a community office for treatment. She has a blood draw followed by a 2-hour chemotherapy infusion. The oncology practice’s office submits a reimbursement claim through Medicare Part B. Two weeks later a notice from Medicare arrives-claim denied!

Why did this happen? The patient was staying in a skilled nursing facility (SNF) at the time of her appointment-a stay that is covered through Medicare Part A. This is called consolidated billing, which is a prospective payment system that covers services within the scope of care at an SNF.

As a result, oncology practices can submit reimbursement claims through Medicare Part B only for those services that are excluded from the consolidated billing package.

Some chemotherapy is excluded from SNF consolidated billing, but other drugs are included. For example, interferon, methotrexate, mesna, leuprolide, and goserelin (Zoladex) are included in SNF consolidated billing.

On the other hand, physicians’ professional services, such as all levels of office visits and most chemotherapy administration services, are excluded from SNF consolidated billing and are reimbursable directly through Medicare Part B.

But then administration of nonchemotherapy drugs and laboratory studies are included in consolidated billing and are reimbursable only through the SNF.

Confusing enough? Here are some simple things that you can do to keep SNF-related billing in order:

• Maintain an up-to-date list of drugs and services included and excluded in SNF consolidated billing.

• Determine whether a patient is an SNF resident at the time an appointment is scheduled.

• Educate patients, caregivers, and staff at local SNFs about the need to inform the practice about the patient’s status when making an appointment.

• Alert the SNF to charges for services included in consolidated billing before the services are provided.

• Continually monitor the status of invoices sent to SNFs and prompt as necessary.

• Establish written payment arrangements with local SNFs. Knowing which services are excluded from SNF consolidated billing and which are included is the most important step in ensuring appropriate billing.

 

Related Videos
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Alexander Spira, MD, PhD, FACP, an expert on lung cancer
A panel of 4 experts on lung cancer
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.